…
Baseline Productions, Inc. does not have significant operations. Previously, the company focused on developing immunotherapeutic based technology related to cancer indication. The company was founded in 2010 and is based in Scottsdale, Arizona.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bassline Productions (BSSP.US) is a publicly quoted company on the OTC Pink market; publicly available disclosures about its operations and financials are sparse. Because corporate details are limited, long-term growth drivers are unclear and will depend on the company's actual business model and execution; investors may find small-cap exposure attractive if transparency and revenue visibility improve.
Primary risks include limited regulatory reporting and transparency, very low trading liquidity typical of OTC Pink listings, potential for operational or financial weakness, and elevated execution and regulatory uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Income before tax | -0.44M | -0.19M | -0.05M | - |
| Net income | -0.44M | -0.19M | -0.05M | -0.09M |
| Selling general administrative | 0.14M | 0.08M | 0.05M | 0.09M |
| Gross profit | 0.00M | 0.00M | 0.01M | - |
| Ebit | -0.18M | -0.08M | -0.04M | -0.09M |
| Ebitda | -0.18M | -0.08M | -0.04M | -0.09M |
| Depreciation and amortization | 0.00M | 0.00M | 0.00M | 0.00M |
| Operating income | -0.18M | -0.08M | -0.04M | -0.09M |
| Other operating expenses | 0.18M | 0.08M | 0.05M | 0.09M |
| Interest expense | 0.10M | 0.11M | 0.01M | 0.00M |
| Income tax expense | 0.10M | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.01M | - |
| Total operating expenses | 0.18M | 0.08M | 0.05M | 0.09M |
| Cost of revenue | 0.00M | 0.00M | 0.00M | - |
| Total other income expense net | -0.16M | -0.11M | -0.01M | - |
| Net income from continuing ops | -0.44M | -0.19M | -0.05M | - |
| Net income applicable to common shares | -0.44M | -0.19M | -0.05M | - |
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Total assets | 0.06M | 0.00M | 0.00M | 0.00M |
| Intangible assets | - | - | 0.00M | 0.00M |
| Other current assets | 0.01M | 0.00M | - | - |
| Total liab | 0.46M | 0.13M | 0.02M | 0.08M |
| Total stockholder equity | -0.41M | -0.12M | -0.02M | -0.08M |
| Other current liab | 0.11M | 0.01M | - | - |
| Common stock | 0.04M | 0.08M | 0.03M | 0.03M |
| Retained earnings | -0.80M | -0.36M | -0.17M | -0.13M |
| Other liab | - | - | 0.00M | - |
| Cash | 0.05M | 0.00M | 0.00M | 0.00M |
| Total current liabilities | 0.37M | 0.12M | 0.00M | - |
| Current deferred revenue | 0.02M | - | - | - |
| Net debt | 0.20M | 0.12M | 0.02M | 0.07M |
| Short term debt | 0.25M | 0.11M | - | - |
| Short long term debt | 0.11M | - | - | - |
| Short long term debt total | 0.25M | 0.12M | 0.02M | 0.08M |
| Other stockholder equity | 0.36M | 0.16M | 0.13M | 0.02M |
| Property plant equipment | 0.00M | 0.00M | - | - |
| Total current assets | 0.06M | 0.00M | 0.00M | 0.00M |
| Net tangible assets | -0.41M | -0.12M | -0.02M | - |
| Long term debt | 0.09M | 0.01M | 0.02M | - |
| Accounts payable | 0.01M | 0.01M | 0.00M | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Investments | -0.00M | -0.05M | -0.05M | - |
| Change to liabilities | 0.02M | 0.01M | 0.01M | - |
| Total cashflows from investing activities | -0.00M | -0.05M | -0.05M | - |
| Net borrowings | 0.23M | 0.13M | 0.04M | - |
| Total cash from financing activities | 0.23M | 0.13M | 0.04M | 0.09M |
| Change to operating activities | -0.01M | -0.00M | -0.00M | - |
| Net income | -0.44M | -0.19M | -0.05M | - |
| Change in cash | 0.05M | -0.00M | -0.00M | -0.00M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 0.01M |
| End period cash flow | 0.05M | 0.00M | 0.00M | 0.00M |
| Total cash from operating activities | -0.18M | -0.08M | -0.04M | -0.09M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.23M | 0.13M | 0.04M | 0.04M |
| Change to netincome | 0.16M | 0.01M | 0.00M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.02M | 0.01M | 0.01M | 0.00M |
| Other non cash items | 0.25M | 0.10M | 0.00M | -0.09M |
| Free cash flow | -0.18M | -0.08M | -0.04M | -0.09M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BSSP Bassline Productions |
- -% |
0.00 | - | - | 8335.00 | - | 8336.65 | -0.64 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Baseline Productions, Inc. does not have significant operations. Previously, the company focused on developing immunotherapeutic based technology related to cancer indication. The company was founded in 2010 and is based in Scottsdale, Arizona.
5423 E. Piping Rock Road, Scottsdale, AZ, United States, 85254
602-326-7371
| Name | Title | Year Born |
|---|---|---|
| Mr. Dennis R. Alexander | Chairman & CEO | 1954 |
| Ms. Joanne M. Sylvanus CPA | CFO, Sec. & Director | 1932 |
| Diana Zhabilov | Pres | NA |
| Ms. Joanne M. Sylvanus CPA | CFO, Secretary & Director | 1932 |
| Diana Zhabilov | President | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.